Lagos-based Sygen Pharmaceuticals Limited and Canada’s ORx Pharmaceuticals Corporation have announced a groundbreaking collaboration to establish Sygen-ORx Biosciences, a joint venture poised to revolutionize healthcare across Africa. This alliance aims to tackle the continent’s pharmaceutical challenges through innovative solutions, merging ORx Pharmaceuticals’ advanced drug development technologies with Sygen Pharmaceuticals’ commitment to scientific excellence and innovation.
ORx Pharmaceuticals, affiliated with the Toronto Institute of Pharmaceutical Technology—North America’s premier postgraduate institute for pharmaceutical research—has a strong reputation for pioneering medical advancements and improving patient care. With a history of delivering transformative therapies and earning industry accolades, ORx brings substantial expertise to this venture. Sygen Pharmaceuticals, a leader in Nigeria’s healthcare sector known for its high-quality medications and innovative treatment approaches, complements ORx’s strengths, creating a dynamic partnership aimed at delivering cutting-edge healthcare solutions in Africa.
Sygen Pharmaceuticals has solidified its position as a key player in Nigeria’s healthcare sector by developing high-quality medications and expanding access to innovative treatments. The formation of Sygen-ORx Biosciences represents a significant milestone in this ongoing mission, uniting the vision and expertise of both companies to enhance patient outcomes and address critical pharmaceutical challenges.
The joint venture will focus on improving formulations of generic pharmaceuticals, with an emphasis on products that demonstrate clinical efficacy, regulatory approval, and commercial success. Additionally, Sygen-ORx Biosciences will lead innovative drug discovery programs, aiming to reduce costs and increase access to high-quality branded generic medicines across Africa.
In support of Sygen-ORx Biosciences, both Sygen and ORx will leverage their extensive global experience in drug discovery, development, commercialization, and distribution. This collaboration is designed to foster open innovation in early-stage drug discovery, accelerate the development of novel therapies, and drive significant advancements in the pharmaceutical field.
“Sygen-ORx Biosciences will build on the strong foundation laid by ORx and Sygen, ushering in a new era of healthcare innovation. With our shared commitment to scientific excellence and integrity, Sygen-ORx Biosciences is positioned to make a profound impact on the healthcare landscape, shaping the future of medicine for generations to come,” stated Dr. Alexander MacGregor, CEO of ORx Pharmaceuticals.
“Collaboration is central to our mission at Sygen Pharmaceuticals, and we are thrilled to embark on this transformative journey with ORx Pharmaceuticals. As Sygen-ORx, we have a unique opportunity to amplify our impact and drive healthcare innovation, ultimately improving the lives of patients in Africa and beyond. Through our partnership, we can leverage our collective strengths to deliver impactful solutions that address critical medical challenges and advance patient care,” added Charles Ogunwuyi, CEO of Sygen Pharmaceuticals.
